MMP-9 and EBA immunoreactivity after papaverine mediated opening of the blood-brain barrier
Related Experiment Video
Updated: Sep 28, 2026

Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
Abesh Kumar Bhattacharjee1, Takeshi Kondoh, Mitsuru Ikeda
1Department of Neurosurgery, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki Cho, Chuo-Ku, Kobe 650-0017, Japan. tkondo@med.kobe-u.ac.jp
Abstract:
Papaverine is a non-specific vasodilatory drug, which was found to unexpectedly cause opening of the blood-brain barrier (BBB). We studied the expression of two endothelial cell related markers, endothelial barrier antigen (EBA) as a marker of BBB intactness, and matrix metalloproteinase-9 (MMP-9), an extracellular matrix molecule, the activation of which results in BBB opening. Immunoreactivity was quantified after intra-carotid injection of papaverine in rats. BBB opening was identified at 1 h, but had been reversed by 24 h. Reduction in EBA-immunoreactivity occurred at 3 h, whereas MMP-9 was not observed until 24 h. The activation of MMP-9 thus occurred much later than BBB opening, which suggests a different role for MMP-9 when selective and reversible opening of the BBB is produced by pharmacological manipulation.

